Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

• Source: Shutterstock

Biocomposites GmbH is launching its NanoBone product range in the UK and making the SYNICEM and Subiton lines fully its own, according to recent announcements from the UK-based innovator of calcium compound and specialty polymer medical devices.

NanoBone SBX Putty and NanoBone QD joined Biocomposites’ portfolio of medical devices for bone regeneration and infection management with its acquisition of Artoss GmbH in June 2023, aiming to expand NanoBone

More from Business

More from Medtech Insight